<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511927</url>
  </required_header>
  <id_info>
    <org_study_id>GH Deficiency in CHF</org_study_id>
    <nct_id>NCT00511927</nct_id>
  </id_info>
  <brief_title>Growth Hormone Deficiency in Chronic Heart Failure: an Observational Study</brief_title>
  <official_title>Observational Study on Prevalence and Prognostic Value of Growth Hormone Deficiency in Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to define the possible detrimental effect of a lack of growth hormone,
      on the well-being and life expectation of patients affected by heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Growth hormone and its main effector IGF-1 have well-documented roles in the regulation of
      cardiac and circulatory function. Evidence suggests that GH/IGF-1 exert a beneficial effect
      on cardiac load, cardiac growth and remodeling, despite their hypertrophying action. Several
      studies in the last years have demonstrated worse cardiovascular outcomes in adult patients
      with GH deficiency and/or low levels of IGF-1.

      A wide range of alterations in the GH/IGF-1 axis have been described to date in patients with
      chronic heart failure (CHF): reductions in GH levels, reductions in IGF-1 and a pattern of
      peripheral resistance to GH, in particular in patients with severe heart failure and cardiac
      cachexia. Our study hypothesis is that an actual status of GH deficiency coexists with CHF in
      a large percent of patients, and that it may represent a predictor of worse functional status
      and possibly of a worse prognosis. Aim of this study is to explore the latter hypothesis,
      comparing the clinical and functional evolution of patients with CHF and GHD with that of a
      general CHF population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">250</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Cardiomyopathy</condition>
  <condition>Heart Failure</condition>
  <condition>Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>GHD</arm_group_label>
    <description>Patients with Growth Hormone Deficiency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-GHD</arm_group_label>
    <description>Patients with CHF, without coexisting growth hormone deficiency</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sera of the patients at time-points upon recruitment and after 12 months
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic heart failure due to left ventricular systolic dysfunction
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Heart Failure: NYHA class II to IV, ACC/AHA stage C/D

          -  Left ventricular end diastolic diameter &gt;60 mm

          -  Left ventricular ejection fraction &lt; 40%

          -  Clinical stability, guideline-oriented top pharmacological therapy

          -  Informed consent

        Exclusion Criteria:

          -  Active Myocarditis

          -  Hypertrophic Cardiomyopathy

          -  Active endocarditis

          -  Active malignancy

          -  End stage renal disease

          -  Severe liver disease (Child B-C)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Cittadini, MD</last_name>
    <role>Study Director</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luigi Sacc√†, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>III Medicina Interna - Federico II University</name>
      <address>
        <city>Naples</city>
        <zip>80100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2007</study_first_submitted>
  <study_first_submitted_qc>August 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2007</study_first_posted>
  <last_update_submitted>February 18, 2014</last_update_submitted>
  <last_update_submitted_qc>February 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Antonio Cittadini</investigator_full_name>
    <investigator_title>Associate Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>heart</keyword>
  <keyword>failure</keyword>
  <keyword>growth</keyword>
  <keyword>hormone</keyword>
  <keyword>igf</keyword>
  <keyword>dilative</keyword>
  <keyword>cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

